Jiaojiao Tan

Dr. Jiaojiao Tan


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2020 in Marine Drugs
Verified
Journal Article
Open access
PDF file
JTJiaojiao Tan
Jiaojiao Tan
JWJing Wang
Jing Wang
Li hua GengLi hua Geng
Li hua Geng
Yang YueYang Yue
Yang Yue
NWNing Wu
Ning Wu
QZQuanbin Zhang
Quanbin Zhang
Nephrotic syndrome (NS) is a clinical syndrome with a variety of causes, mainly characterized by heavy proteinuria, hypoalbuminemia, and edema. At present, identification of effective and less toxic therapeutic interventions for nephrotic syndrome remains to be an important issue. In this study, we isolated fucoidan from Saccharina japonica and prepared its depolymerized fragment by oxidant degradation. Fucoidan and its depolymerized fragment had similar chemical constituents. Their average molecular weights were 136 and 9.5 kDa respectively. The effect of fucoidan and its depolymerized fragment on adriamycin-induced nephrotic syndrome were investigated in a rat model. The results showed that adriamycin-treated rats had heavy proteinuria and increased blood urea nitrogen (BUN), serum creatinine (SCr), total cholesterol (TC), and total triglyceride (TG) levels. Oral administration of fucoidan or low-molecular-weight fucoidan for 30 days could significantly inhibit proteinuria and decrease the elevated BUN, SCr, TG, and TC level in a dose-dependent manner. At the same dose (100 mg/kg), low-molecular-weight fucoidan had higher renoprotective activity than fucoidan. Their protective effect on nephrotic syndrome was partly related to their antioxidant activity. The results suggested that both fucoidan and its depolymerized fragment had excellent protective effect on adriamycin-induced nephrotic syndrome, and might have potential for the treatment of nephrotic syndrome.

22 August 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
JLJiang Li
Jiang Li
JTJiaojiao Tan
Jiaojiao Tan
JLJunjie Liu
Junjie Liu
MWMinghui Wang
Minghui Wang
XGXiaoqian Gu
Xiaoqian Gu
XPXinning Pan
Xinning Pan
Background: Marine algal oligosaccharide (MAO) molecular structural characteristics are closely related to their bioactivity. However, an understanding of the specific relationships between MAO molecular structure (including polymerization degree [DP] and sulfate groups) and bioactivity is lacking. Methods: In this work, laboratory-prepared DP4 and DP8 MAOs, including agar- (AOs) and κ-, ι-, and λ-carrageenan-oligosaccharides (COs), were examined for their anti-inflammatory activity in RAW264.7 macrophages and therapeutic effect on colitis in mice; additionally, the potential mechanisms involved were explored. Results: The results showed that CO (ι- and λ-COs) anti-inflammatory activity was higher than that of AOs and was positively correlated with sulfate group content. MAOs with different structures all alleviated colitis symptoms; those with higher sulfate group content and DP showed excellent therapeutic efficacy. MAOs modulated gut microbiota and promoted the enrichment of microbiota-derived short-chain fatty acid production (butyrate), which potentially induced PPARγ signaling and contributed to the impacts of MAOs on mucosal homeostasis restoration. Conclusions: Therefore, MAOs with higher sulfate content and DP showed improved therapeutic efficacy compared with those with lower contents, which involved higher SCFA production.